SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Rubius Therapeutics, Inc. – ‘15-12G’ on 4/10/23

On:  Monday, 4/10/23, at 4:17pm ET   ·   Effective:  4/10/23   ·   Accession #:  1104659-23-43593   ·   File #:  1-38586

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/10/23  Rubius Therapeutics, Inc.         15-12G      4/10/23    1:12K                                    Toppan Merrill/FA

Certification of a Termination of Registration of a Class of Securities   —   Form 15   —   § 12(g) – SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 15-12G      Certification of a Termination of Registration of   HTML     11K 
                a Class of Securities                                            


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 15

 

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934.

 

001-38586

Commission File Number

 

 

 

RUBIUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

c/o Verdolino & Lowey, P.C.

124 Washington Street, Suite 101

Foxborough, MA 02035

(508) 543-1720

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, par value $0.001 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1) x
Rule 12g-4(a)(2) ¨
Rule 12h-3(b)(1)(i) x
Rule 12h-3(b)(1)(ii) ¨
Rule 15d-6 ¨
Rule 15d-22(b) ¨

 

Approximate number of holders of record as of the certification or notice date: fourteen (14)

 

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Rubius Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: April 10, 2023   RUBIUS THERAPEUTICS, INC.
       
       
    By: /s/ Craig Jalbert
    Name: Craig Jalbert
    Title: President

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘15-12G’ Filing    Date    Other Filings
Filed on / Effective on:4/10/23SC 13G/A
 List all Filings 
Top
Filing Submission 0001104659-23-043593   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 7, 1:55:06.1pm ET